Yatsen (YSG) Q2 2026 Earnings Call Transcript

Yatsen reported Q2 2026 revenue growth of 5.1% to RMB1.14 billion, but its net loss widened to RMB90.8 million from RMB19.5 million a year earlier as gross margin fell 440bps to 73.9% and selling and marketing costs rose to 70.7% of revenue. Skincare revenue grew 40.4% and reached 71.5% of sales, but color-cosmetics revenue declined 35.8% amid SKU rationalization and inventory provisions. Management guided Q3 revenue to RMB898.6 million-RMB998.4 million, implying flat to a 10% year-over-year decline, while pursuing lower-cost B2B distribution and AI-enabled operating efficiencies.

Analysis

YSG’s issue is not category demand but unit economics: paid traffic inflation is absorbing the gross-profit pool before fixed costs, while the legacy portfolio still requires cash and inventory cleanup. A skincare-led mix shift can improve revenue quality only if repeat purchase and offline/B2B sell-through lower customer-acquisition cost; otherwise, growth through Douyin simply scales losses. With operating cash flow now negative and cash roughly flat, the relevant valuation risk over the next 2-3 quarters is a shrinking runway rather than a conventional earnings multiple reset.

The most consequential second-order effect is channel bargaining power. YSG’s push into JD, PDD, VIPS and Alibaba ecosystems may diversify traffic sources, but these marketplaces can demand discounting, commissions, and promotional funding; it does not automatically create margin relief. JD is the relative potential beneficiary if premium skincare distribution moves toward authenticated, fulfillment-intensive channels, while PDD/VIPS could gain incremental GMV but risk becoming clearance outlets that dilute brand positioning. The broader implication for Chinese beauty is that scaled domestic incumbents with superior repeat rates and owned-channel traffic should take share as smaller brands cannot profitably match content-spend intensity.

Consensus may overfocus on reported gross-margin damage as a one-time inventory event. The larger concern is that marketing intensity remains structurally elevated even after excluding provisions, making management’s profitability timeline dependent on unproven conversion of B2B and AI initiatives into measurable CAC and retention improvement. A contrarian long is only justified if the next two quarters demonstrate sequential marketing leverage and positive operating cash flow; absent that, weak guidance leaves downside skewed, particularly in a thinly traded ADR.

Key Decisions for Investors

• Maintain/establish a 1-3 month short YSG only on post-earnings liquidity or a relief rally; target a 15-25% downside if the next update fails to show sequential selling-and-marketing leverage. Cover if skincare growth reaccelerates while selling and marketing falls below 65% of revenue or operating cash flow turns positive.
• Do not use JD, PDD, VIPS, or BABA as directional read-through longs: YSG is too small to be financially material. Instead, monitor their quarterly beauty GMV, take rates, and promotional subsidies as evidence of whether YSG’s channel diversification is margin-accretive or merely shifts acquisition costs into marketplace fees.
• Set an earnings watch item for Q3/Q4: require disclosure of channel-level CAC, repeat purchase, B2B sell-through, and inventory provisions before considering a long. A sustainable rerating needs at least two consecutive quarters of revenue stability plus a 500-700bp reduction in marketing intensity, not just skincare mix growth.
• For portfolios requiring China consumer exposure, prefer a quality-barbell pair: long JD versus short YSG over 6-12 months. JD benefits from premium-brand fulfillment and consumer trust, whereas YSG remains exposed to traffic-cost inflation and brand-transition execution; reassess if YSG demonstrates independently verified B2B margin expansion.